<DOC>
	<DOCNO>NCT00291382</DOCNO>
	<brief_summary>This double-blind , stratify , parallel group study determine whether aim 'Total control ' result well airway hyper-responsiveness maintain treatment level 'Well-controlled ' asthma achieve . The primary endpoint mean change PC20 methacholine . Well controlled subject ( assess 12 week run-in period ) enter 24 week treatment period record PEF ( Peak Expiratory Flow ) , symptom , rescue beta2-agonist use 24 hour , night time awakening , asthma exacerbation , emergency visit due asthma Adverse Events . At every visit lung function measurement airway hyper-responsiveness measure .</brief_summary>
	<brief_title>Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product</brief_title>
	<detailed_description>A multi-centre , randomise , double blind , stratify , parallel group study evaluate whether treatment strategy base aim 'Total control ' result well airway hyper-responsiveness treatment strategy base maintain treatment level 'Well-controlled ' asthma achieve .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Respiratory Hypersensitivity</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : History asthma least 6 month . Subjects receive fluticasone propionate dose 100 mcg bd 250 mcg bd equivalent without long act beta2agonist least 4 week start runin period , constant dose . Subjects able understand complete electronic diary card . Exclusion criterion : Subjects hospitalize asthma within 4 week study entry . Subjects acute upper respiratory tract infection within 4 week low respiratory tract infection within 4 week prior study entry . Subjects received oral , parental depot corticosteroid within 4 week prior study entry . Subjects know respiratory disorder asthma and/or systemic/thoracic abnormality influence normal lung function . Subjects 5 pack year . Subjects currently smoke .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Total asthma control</keyword>
	<keyword>airway hyper-responsiveness</keyword>
	<keyword>adult</keyword>
	<keyword>Asthma</keyword>
</DOC>